MedTrace Logo

Zhibitai Capsules for the Treatment of Primary Hyperlipidemia

NCT06822946 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2025-11-20

No results posted yet for this study

Summary

Exploring the benefit risk ratio of increase in dosage of Zhibitai capsules (2 capsules at a time, 2 times a day) compared to the original dosage (1 capsule at a time, 1 day)

Conditions

  • Primary Hyperlipidemia

Interventions

DRUG

zhibitai capsule

2 capsule of Zhibitai capsule/time, 2 times/day, oral

DRUG

zhibitai capsule

(1 capsule of Zhibitai capsules+1 capsule of Zhibitai capsule simulant)/time, 2 times/day, oral

Sponsors & Collaborators

  • Chengdu Diao Jiuhong Pharmaceutical Factory

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-27
Primary Completion
2026-02-28
Completion
2026-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06822946 on ClinicalTrials.gov